Pharm final Flashcards
Stereoisomerism
Same chemical formula but different 3D structure and drug effects
differ toxins and poisons
Toxins are biological (snake venom) while poisons are pharmaceutical (cyanide, arsenic, alcohol)
Strongest combination of agonists, weakest?
Agonist + allosteric activator
Agonist + allosteric inhibitor
Pharmacokinetics vs pharmacodynamics
What the body does to the drug (ADME) vs what the drug does to the body (effects, binding, etc.)
If pH < pKa
favors protonated form (has Hydrogen attached)
if pH > pKa
Favors unprotonated form (no Hydrogen ion attached)
Weak Acid: pKa 3.5, pH 1.5
Protonated, non-charged
Weak base: pKa 7.0, pH 4.5
Protonated, Charged
Weak Acid: pKa 2.5, pH 5.0
Unprotonated, charged
Weak base: pKa 4.0, pH 6.5
Unprotonated, non-charged
What’s the therapeutic ratio?
TD50/ED50
Most potent curve on graph is
the one that starts showing effect the earliest
What’s the goal of rational dosing?
Achieve desired beneficial effect with minimal adverse effects
the bond strength is indirectly proportional to
specificity
Drug safety is directly proportional to
therapeutic index
Volume of distribution is directly proportional to
concentration of drug outside systemic circulation
First order elimination vs zero order elimination
first order elimination elimination rate changes with concentration, whereas zero-order has max and CONSTANT elimination rate until it reaches first order concentration levels.
In first order, the fraction elimination rate is constant. e.g. 10% of the drug is eliminated every hour, so the elimination rate changes but not the fractional change
How long does it take a drug to reach full effectiveness if the half-life is 4 hours?
How long does it take to be removed from the body/no effectiveness?
16 hours (4 half-lives), then another 16 hours. Totals 32 hours.
Parameters that affect passive diffusion
Weight of the drug, pKa, lipid solubility, and plasma protein binding
Four basic mechanisms of transmembrane signaling
-Direct crossing to intracellular receptor due to having lipid solubility (think aldosterone)
- Enzymatic action mediated by ligand binding (TKR)
-Ligand gated ion channel (ACH in skeletal muscle)
-GPCRs
GPCR structure
- 7 trans-membrane alpha-helices
-Pleiotropy: several downstream effects possible
-G-proteins: trimeric
-alpha subunit dissociates when active (GDP -> GTP) and binds to effector protein to produce second messenger cells)
Describe desensitization
The GPCR is phosphorylated by GRKs, enabling beta-arrestin to bind to the phosphorylated receptor, thereby inactivating it. The receptor-beta-arrestin complex is then internalized into a clathrin-coated pit, where the receptor can either be recycled to the membrane or degraded in lysosomes
Drug efflux transporters
- ATP-binding cassete (ABC) transporters
-major drug efflux transporters are B, C, G and found in
Where are B C and G ABC drug efflux transporters found?
Intestines, liver, kidneys, BBB, placenta
What’s the research target of the blood brain barrier?
Block efflux transporters, increase delivery to brain
tight junction!!
Biotransformation
Some drugs become active AFTER going through liver, but it could also be inactivation of metabolite
Examples of second messengers in a GPCR activation cascade
DAG
cAMP
IP3
cGMP
adenylyl cyclase is NOT a second messenger!!!
Neurotransmitter class: Esters
ACh - Cholinergic
Neurotransmitter class: Monoamines
Norepi, serotonin, dopamine - ADRENERGIC
Neurotransmitter class: Amino acids
Glutamate, GABA
Neurotransmitter class: Purines
Adenosine, ATP
Neurotransmitter class: Peptides
Substance P, endorphins
Neurotransmitter class: Inorganic gases
Nitric oxide
Sympathetic vs parasympathetic fibers
Symp: thoracolumbar region of spinal cord, consists of short pre and long post
Para: brain and sacral region, long pre and short post
a1 and a2 activates what?
Phospholipase C
b1 2 and 3 stimulates what?
Adenylate cyclase
M1 3 and 5 activate what?
Phospholipase
M2 and 4 inhibit what?
andeylate cyclase
MOA of phospholipase C activation (whole pathway)
Agonist binds to a1 receptor, GDP -> GTP, alpha subunit binds to effector protein phospholipase C, secrets DAG and IP3, releases stored calcium
MOA of adenylyl cyclase activation (whole pathway)
Agonist binds to beta receptor or a2 receptor, alpha subunit turns to GTP, stimulates effector protein adenylyl cyclase, ATP -> cAMP, activates protein kinase -> downstream effects
Receptors in heart for sympathetic activity are
B1 and B2
Receptors on skeletal muscle blood vessels
B2